Astria Therapeutics (ATXS) Free Cash Flow: 2017-2019
Historic Free Cash Flow for Astria Therapeutics (ATXS) over the last 3 years, with Dec 2019 value amounting to -$7.8 million.
- Astria Therapeutics' Free Cash Flow fell 47.47% to -$7.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$26.6 million, marking a year-over-year decrease of 13.23%. This contributed to the annual value of -$81.5 million for FY2024, which is 19.08% down from last year.
- As of Q4 2019, Astria Therapeutics' Free Cash Flow stood at -$7.8 million, which was down 20.02% from -$6.5 million recorded in Q3 2019.
- Astria Therapeutics' 5-year Free Cash Flow high stood at -$5.3 million for Q4 2018, and its period low was -$8.1 million during Q1 2017.
- Over the past 3 years, Astria Therapeutics' median Free Cash Flow value was -$6.1 million (recorded in 2018), while the average stood at -$6.4 million.
- As far as peak fluctuations go, Astria Therapeutics' Free Cash Flow climbed by 22.30% in 2018, and later tumbled by 47.47% in 2019.
- Astria Therapeutics' Free Cash Flow (Quarterly) stood at -$5.6 million in 2017, then rose by 6.53% to -$5.3 million in 2018, then tumbled by 47.47% to -$7.8 million in 2019.
- Its Free Cash Flow stands at -$7.8 million for Q4 2019, versus -$6.5 million for Q3 2019 and -$5.7 million for Q2 2019.